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Characterization of resistance to a potent
d‑peptide HIV entry inhibitor
Amanda R. Smith1†, Matthew T. Weinstock1†, Amanda E. Siglin2, Frank G. Whitby1, J. Nicholas Francis1,
Christopher P. Hill1, Debra M. Eckert1, Michael J. Root2 and Michael S. Kay1*

Abstract
Background: PIE12-trimer is a highly potent d-peptide HIV-1 entry inhibitor that broadly targets group M isolates.
It specifically binds the three identical conserved hydrophobic pockets at the base of the gp41 N-trimer with subfemtomolar affinity. This extremely high affinity for the transiently exposed gp41 trimer provides a reserve of binding
energy (resistance capacitor) to prevent the viral resistance pathway of stepwise accumulation of modest affinitydisrupting mutations. Such modest mutations would not affect PIE12-trimer potency and therefore not confer a
selective advantage. Viral passaging in the presence of escalating PIE12-trimer concentrations ultimately selected for
PIE12-trimer resistant populations, but required an extremely extended timeframe (> 1 year) in comparison to other
entry inhibitors. Eventually, HIV developed resistance to PIE12-trimer by mutating Q577 in the gp41 pocket.
Results: Using deep sequence analysis, we identified three mutations at Q577 (R, N and K) in our two PIE12-trimer
resistant pools. Each point mutant is capable of conferring the majority of PIE12-trimer resistance seen in the polyclonal pools. Surface plasmon resonance studies demonstrated substantial affinity loss between PIE12-trimer and the
Q577R-mutated gp41 pocket. A high-resolution X-ray crystal structure of PIE12 bound to the Q577R pocket revealed
the loss of two hydrogen bonds, the repositioning of neighboring residues, and a small decrease in buried surface
area. The Q577 mutations in an NL4-3 backbone decreased viral growth rates. Fitness was ultimately rescued in resistant viral pools by a suite of compensatory mutations in gp120 and gp41, of which we identified seven candidates
from our sequencing data.
Conclusions: These data show that PIE12-trimer exhibits a high barrier to resistance, as extended passaging was
required to develop resistant virus with normal growth rates. The primary resistance mutation, Q577R/N/K, found in
the conserved gp41 pocket, substantially decreases inhibitor affinity but also damages viral fitness, and candidate
compensatory mutations in gp160 have been identified.
Keywords: HIV entry inhibition, d-peptide, PIE12-trimer, gp120, gp41, Viral resistance mutation, Hydrophobic pocket,
Viral fitness, Compensatory mutation, Viral passaging

*Correspondence: kay@biochem.utah.edu
†
Amanda R. Smith and Matthew T. Weinstock contributed equally to this
work
1
Department of Biochemistry, University of Utah School of Medicine, Salt
Lake City, UT 84112, USA
Full list of author information is available at the end of the article
© The Author(s) 2019. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium,
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license,
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Smith et al. Retrovirology

(2019) 16:28

Background
Approximately 37 million people are living with Human
Immunodeficiency Virus (HIV), a virus that has resulted
in an estimated 35 million deaths due to Acquired Immunodeficiency Syndrome (AIDS) [1]. Combination antiviral therapeutics targeting various stages of the viral
lifecycle have dramatically improved the clinical outcome
for those with access to treatment, but viral resistance
has been documented for all approved drugs [2]. This
resistance is facilitated by a high mutation rate (due to a
low-fidelity viral reverse transcriptase, frequent recombination events, rapid turnover of the virus, and host
APOBEC3 activity) in the face of the selective pressure of
the drug [3–5].
We previously reported the discovery and design
of an extremely potent d-peptide HIV-1 entry inhibitor (PIE12) that targets the HIV envelope protein (Env)
using sequential rounds of mirror-image phage display
and high-resolution structure-guided design [6–9]. With
the opposite chirality of naturally occurring l-peptides,
d-peptides (composed of d-amino acids) are not recognized by natural proteases. This property confers longer
in vivo half-lives and reduced immunogenicity, which are
potentially significant therapeutic advantages [7]. The
target of PIE12 is the highly conserved pocket at the base
of the gp41 N-trimer, a parallel trimeric coiled-coil region
of gp41 that is transiently exposed (“prehairpin intermediate”) during HIV-1 entry. The N-trimer pocket is an
appealing antiviral target due to its high conservation,
extracellular accessibility, and its vital role in viral entry.
Our inhibitor harnesses avidity for this trimeric pocket,
as three d-peptide monomers are covalently linked via an
optimized PEG-based scaffold (PIE12-trimer), and binds
the N-trimer with sub-fM affinity [8, 10]. PIE12-trimer
prevents the folding of the N-trimer and C-peptide
regions of gp41 into the 6-helix bundle (trimer-of-hairpins) structure required for membrane fusion during
viral entry, and it inhibits all members of a diverse panel
of primary Group M HIV isolate strains with high pM to
low nM potency (IC50) [8].
The remarkable conservation of this gp41 hydrophobic pocket target [6] is indicative of its critical roles in
the viral life cycle and impedes the ability of the virus
to combat inhibitors that target it. The region of the
HIV-1 genome encoding the pocket is conserved at
both the protein level (for the role of gp41 in membrane
fusion during viral entry) and nucleotide level (due to a
structured RNA region in the critical Rev-response element). The only FDA-approved HIV fusion inhibitor,
enfuvirtide (Fuzeon), is an l-peptide derived from the
gp41 C-peptide region that targets the gp41 N-trimer
region adjacent to, but not including, the hydrophobic pocket and induces the rapid emergence of gp41
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resistance mutations both in vitro and in vivo [11, 12].
Next-generation l-peptide fusion inhibitors (such as
T-1249 and T-2635), whose binding footprint extends
into the pocket, are much less impacted by enfuvirtide
resistance mutations. Viral escape from these inhibitors generally takes longer to appear but still involves
resistance mutations located outside the pocket region
[13–16].
In addition to targeting a highly conserved, functionally
critical region of the virus, PIE12-trimer was designed
with an additional barrier to viral resistance called the
“resistance capacitor”. The gp41 N-trimer is transiently
exposed during HIV entry in a prehairpin intermediate
conformation [17]. The potency of a variety of high-affinity prehairpin intermediate-targeting inhibitors has been
shown to vary with changes in association kinetics rather
than affinity, reflective of the kinetically limited availability of the target [8, 9, 18–20]. Once a threshold association rate is reached, additional affinity enhancement fails
to improve antiviral potency. We chose to “over-engineer” PIE12-trimer such that its pocket-binding affinity
far surpassed its potency. This excess binding energy, or
resistance capacitor, should prevent the accumulation
of incremental mutations that modestly disrupt inhibitor affinity, as such mutations would not affect potency
and would therefore fail to confer a selective replicative
advantage. Instead, the virus would be forced to combat
PIE12-trimer with a strongly disruptive mutation, likely
at the cost of viral fitness.
Several lines of evidence suggested that PIE12-trimer
would exhibit a high barrier to resistance. First, PIE12trimer is estimated to bind with sub-fM affinity and
inhibit with low nM potency, characteristic of a “highly
charged” resistance capacitor [8]. Second, PIE12-trimer
exhibits higher potency against polyclonal viruses
derived from infected patients than does an earlier generation d-peptide trimer with lower affinity, demonstrating its better tolerance of Env sequence variation. Finally,
PIE12-trimer maintains potency against virus resistant to
PIE7-dimer, a lower affinity d-peptide. Indeed, consistent
with a “highly charged” resistance capacitor, we observed
a significant delay in the selection of HIV-1 resistant to
PIE12-trimer compared to selections against enfuvirtide
and earlier-generation d-peptides [8].
Expanding on our earlier work that selected for viral
resistance to PIE12-trimer, here we describe the biochemical, structural, and functional properties of the primary PIE12-trimer resistance mutations (Q577R/N/K).
These mutations substantially disrupt PIE12-trimer
affinity and significantly decrease viral fitness. Through
comprehensive characterization of the genotype of our
PIE12-trimer resistant viral populations via next-generation sequencing, we identify potential compensatory
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mutations in HIV Env that restore fitness in the context
of Q577R/N/K.

Results
Primary resistance to PIE12‑trimer arises via mutation
of Q577 in the gp41 hydrophobic pocket

We previously reported the selection of HIV-1 populations resistant to PIE12-trimer by passaging the
lab-adapted NL4-3 strain in the presence of escalating suboptimal (partially inhibiting) concentrations of
inhibitor, starting with 1 nM. Ultimately, PIE12-trimer
resistant virus propagating in 320 nM PIE12-trimer
was obtained after 65 weeks of passaging [8]. Duplicate
selections yielded two highly resistant polyclonal viral
pools (W1 and W2). As previously reported, similar passaging studies with enfuvirtide led to high-level resistance (> 1000-fold) within ~ 3 weeks [8]. Both W1 and
W2 showed > 650-fold loss of sensitivity to PIE12-trimer
while retaining full susceptibility to the C-peptide inhibitor, C37, demonstrating the ability of the virus to specifically resist PIE12-trimer while maintaining the native
interaction between the N-trimer and C-peptide (Fig. 1
and Table 1).
Early analysis of a limited number of clones from the
W2 resistant pool via Sanger sequencing identified the
mutation Q577R within the gp41 hydrophobic pocket
in all clones [8]. In an HXB2 pseudovirion, Q577R confers > 4000-fold resistance to PIE12-trimer [10]. Here,
to characterize the genetic basis of resistance and to
understand the penetrance of the Q577R mutation, we
deep sequenced the W1 and W2 viral pools, as well as a
pNL4-3 control viral pool that had been propagated in
the absence of inhibitors. This more extensive sequencing
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Table 1 Inhibition of replication-competent HIV-1 (NL4-3
backbone)
PIE12-trimer (nM)

C37 (nM)

NL4-3 (WT)

1.33 (0.79)

11.2 (4.07)

W1 (resistant pool)

999 (176)

7.62 (2.18)

W2 (resistant pool)

894 (419)

14.9 (1.31)

Q577R

188 (63)

ND

Q577 N

164 (105)

ND

Q577K

128 (59)

ND

Average IC50 values for clonal NL4-3 (WT), PIE12-trimer 320 nM polyclonal
resistant pools (W1 and W2), and Q577 point mutations in the NL4-3
background. Values are averages of IC50’s fit from two independent experiments
with triplicate measurements. Standard deviations are shown in parentheses
ND not determined

(with an average sequencing depth of > 200,000 reads per
nucleotide position) revealed two distinct mutations at
position Q577 (codon CAG) in the highly resistant pools:
N (codon AAC) in W1 and R (codon CGG) in W2. Q577
is mutated in virtually all of the resistant virus (> 97% of
the sequences in W1 and W2), and there were no spontaneous Q577 mutations in the control population (Additional file 1). Additionally, there are no other positions
within the gp41 pocket that are mutated.
Q577R only requires a single nucleotide change, while
Q577N requires a double mutation and likely occurs
stepwise. To determine which pathway the virus took
to acquire the Q577N substitution, we deep sequenced
this N-trimer region from an intermediate pool of virus
isolated at an earlier timepoint during resistance selection and noted an equal ratio of N (AAC) and K (AAG)
(data not shown). In the context of replication-competent
virus (NL4-3 strain), each Q577 mutant (R, N or K) confers substantial resistance to PIE12-trimer (~ 100-fold)
and accounts for the majority of the loss of sensitivity to
PIE12-trimer (Fig. 1 and Table 1).
Mutation of Q577 significantly decreases PIE12‑trimer
affinity for the gp41 pocket

Fig. 1 Representative inhibitory curves of replication-competent
NL4-3 (WT) and PIE12-trimer resistant viruses. The polyclonal viral
pools (W1 and W2) show slightly enhanced resistance compared
to clonal virus expressing Env with Q577 point mutations.
Representative normalized data are shown from a single assay with
triplicate measurements (error bars show standard error). IC50 values
of this representative data set are indicated in parentheses

To determine the impact of Q577 mutation on PIE12
binding affinity, Q577R was incorporated into an N-peptide mimic (IZN36 [17]), and the interaction was analyzed via surface plasmon resonance (SPR). Because
PIE12-trimer affinity is too tight to accurately measure
via SPR [8], monomeric PIE12 was flowed over the IZN36
(WT and Q577R) surfaces. The Q577R mutation results
in a dramatic (~ 65-fold) weakening of the interaction
between PIE12-monomer and the hydrophobic pocket
(Q577R KD = 2.0 µM vs. 0.031 µM for WT) (Fig. 2 and
Additional file 2), corresponding to a 2.5 kcal/mol weakening of the PIE12 interaction. Because our inhibitor is
trimeric, we expect the impact on PIE12-trimer’s binding
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Table 2 Crystallographic data and refinement statistics
Q577R
Data
Processing software

HKL2000

Space group

R3 (48.8, 48.8, 67.6)

Resolution (Å)

50.0–1.30

Resolution (Å) (high-resolution shell)

(1.35–1.30)

# Reflections measured

144,573

# Unique reflections

14,571

Redundancy

9.9

Completeness (%)

98.5 (99.7)

  < I/σI>
Fig. 2 Protein interaction analysis of Q577R mutation. SPR
equilibrium binding data (in triplicate) for interaction between
immobilized IZN36 (WT or Q577R) and PIE12 monomer. The
calculated KD values are 0.031 µM for WT and 2.0 µM for Q577R

energy to be three times as great, corresponding to a
geometric drop of binding affinity of 653 (or > 250,000).
This large decrease in binding affinity is consistent with
the prediction that an extremely disruptive mutation
is required to overcome PIE12-trimer’s highly charged
resistance capacitor.
Crystal structure of PIE12 in complex with the Q577R
mutation

To understand the molecular basis of Q577R-induced
resistance, monomeric PIE12 was crystallized in complex with an HIV-1 N-trimer pocket mimic (IQN17
[17]) with the Q577R substitution, and the structure
was determined at 1.3 Å resolution (Table 2, PDB code
6PSA). As in all previous d-peptide/IQN17 structures
[6, 8, 9], IQN17 forms a continuous trimeric coiled
coil with the d-peptide binding to the gp41 hydrophobic pocket region. When compared to each of our previously reported structures of PIE12 binding to WT
IQN17 (PDB codes 3L35, 3L36, and 3L37) [8], the overall
structure agrees well, with root mean square deviations
(RMSD) of ≤ 1.0 Å for all Cα atoms. A representative
overlay of the mutant and WT structures (using 3L37,
the WT structure with the lowest RMSD, 0.34 Å), centered around position 577 of the hydrophobic pocket is
shown in Fig. 3. In the WT structure, Q577 hydrogen
bonds with d-Glu9 and d-Trp12 in PIE12 [8]. Q577R disrupts these hydrogen bonds, likely accounting for the loss
of affinity, and induces a repositioning of two adjacent
residues (d-Glu9 in PIE12 and L581 in IQN17, although
d-Glu9 position is variable in the WT structures). These
structural changes lead to a minimal change in the buried
surface area of the inhibitor interface with the N-trimer

7 (2.1)

CC1/2

0.985 (0.973)

Mosaicity (o)

0.62

Rpim

0.038 (0.128)

Refinement
Refinement software

PHENIX.REFINE

Resolution (Å)

50.0–1.30

Resolution (Å)—(high-resolution shell)

(1.347–1.300)

# Reflections used for refinement

14,461

# Reflections in Rfree set

1445

Rcryst

0.190 (0.249)

Rfree

0.240 (0.282)

RMSD: bonds (Å)/angles (°)

0.008/1.044

  < B > (Å2): all protein atoms/# atoms

23.9/530

  < B > (Å2): solvent molecules/#water + 2 chloride
ions

40.7/76

φ/ψ most favored (%)/additionally allowed (%)

100/0.0

target (555 and 524 Å2 in the WT and mutant structures,
respectively).
Mutation of Q577 causes a significant viral growth defect

The extended time required for evolution of high-level
PIE12-trimer resistance in passaging studies (65 weeks)
and the high sequence conservation of the inhibitor
binding site on gp41 suggest that the primary Q577
resistance mutations come with a fitness cost to the
virus. We therefore investigated the growth kinetics
of the NL4-3-based replication competent Q577 point
mutants and the polyclonal viral pools (W1 and W2)
and compared them to that of the native virus (clonal
NL4-3, WT). Starting with a virus inoculum containing 1 ng p24, indeed, the growth of the Q577 mutants
is significantly decreased compared to WT (Fig. 4).
Q577R and Q577K did not propagate significantly during the entire course of the assay, while Q577N replication was substantially delayed. Interestingly, the
PIE12-trimer resistant polyclonal pools (W1 and W2)
show similar growth kinetics to WT virus, suggesting
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Fig. 3 Crystal structures of PIE12/IQN17 (Q577R) (PDB: 6PSA) and PIE12/IQN17 (WT PDB:3L37). Stereoview of the overlay of crystal structures of
PIE12 binding to the WT (yellow) and a mutant (Q577R, turquoise) pocket showing the disruption of hydrogen bonding interactions mediated by
Q577

Identification of potential compensatory mutations
to overcome the Q577 fitness defect

Fig. 4 Viral Growth Assays. Comparison of growth kinetics between
control clonal NL4-3 (WT), Q577 mutant viruses (R, N and K),
and resistant polyclonal viral pools (W1 and W2). Viral titers were
determined by qRT-PCR and compared to a standard curve of
known HIV-1 titers (based on p24 antigen levels). Each culture was
inoculated with virus containing 1 ng p24 (average of biological
duplicate assays shown with s.d. error bars)

that compensatory mutations rescue the fitness defect
associated with the Q577 mutants. WT, W1, and W2
all show rapid growth and hit similar peak p24 levels.
Importantly, starting viral titers of the Q577 mutant
stocks (normalized to p24) vary significantly from WT,
ranging from greatly reduced (~ 40-fold for Q577K
and ~ 7-fold for Q577R) to increased (~ threefold for
Q577N). Additionally, although the output viral population was not sequenced, it is possible the Q577N
sample regained replication fitness by reverting to WT
during the course of the assay since it was not under
the selective pressure of PIE12-trimer.

To identify additional mutations that arose during the
selection for resistance, the entire env gene for each
resistant pool (and control pool propagated in the
absence of inhibitor) was deep sequenced. To complement these short reads and obtain linkage information,
we also performed Sanger sequencing on 13 PIE12trimer resistant clones (five from W1 and eight from
W2). This search should identify mutations that compensate for the fitness defects associated with Q577R/N/K as
well as those that contribute modestly to PIE12-trimer
resistance, as W1 and W2 are slightly more resistant than
the Q577 mutants alone (Fig. 1 and Table 1).
Using the deep sequencing data, we identified all point
mutations, insertions, and deletions within the env gene
of the PIE12-trimer resistant populations with > 10%
absolute difference in abundance from the control pool
(Table 3 and Additional file 1). We predict that 10% is a
high enough threshold to filter out noise due to genetic
drift and sequencing errors, but low enough to catch
minor variations in the population that could contribute
to resistance. Following these guidelines, 25 candidate
protein mutations (74 env nucleotide positions) were
identified for further analysis.
To focus our analysis on a more limited set of mutations most likely to contribute to resistance and fitness compensation, we narrowed our list to the those
that were not silent (except in the Rev Response Element (RRE), where a silent mutation could impact RNA
structure) and with the highest penetrance (> 50% abundance in both resistant viral pools but not in the control).
Eight mutations meet these criteria (indicated in italics
in Table 3). Interestingly, when we compared the clonal
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Table 3 Amino acid changes in HIV-1 Env in polyclonal viral pools with high-level PIE12-trimer resistance
Mutation

Codon

Prevalence
Control (%)

T19I
A48T
E83K
N136D
N136K
R146K
Δ161–164
F175L
V200E
V255A
N301K
S306R
T319A
Δ396–400
N460I
G464E
S465P
Q550H
Q577R
Q577N
V583V
A612T
H643Y
L663F
N674T
V693I
A823 V

acc → atc

gca → aca

32

aat → aag

47

aga → aaa

gtc → gaa
aac → aaa

72

57

20

10

99

99

18

24

90

ttc → ctc

gta → gca

glycosylation site

90

V1/V2, glycosylation site

67

V1/V2

46
71

aca → gca

100

99

glycosylation site

64

20

V3

59

V4, glycosylation site

17

near CD4 binding site

85
58

aat → att

ggg → gag

82

cag → cac

92

cag → aac

97

tcc → ccc

glycosylation site
11

cag → cgg
gtg → gta
cac → tac

Notes

67

agt → aga

gct → act

W2 (%)

44

gaa → aaa
aat → gat

W1 (%)

100

98

N-trimer, RRE

99

PIE12 binding site, RRE

100

13
99

tta → ttt

gta → ata
gct → gtt

glycosylation site, RRE

46

97

99

99

aac → acc

silent/RRE

56

C-peptide
glycosylation site

21
98

99

List of amino acid mutations (point mutant, insertion or deletion) in either resistance pool that occurs at a rate > 10% different than in the control pool. In italic are the
mutants that meet the stricter criteria of: (1) high prevalence (≥ 50%) within both resistant populations but not in the control, (2) not silent (except in the RRE, where a
silent mutation could impact RNA structure)

Sanger sequence data to these final mutations of interest,
all but one are present in every clone. Only A48T lacked
100% penetrance and was found in 3/5 W1 and 3/8 W2
clones.
In addition to identifying the primary resistance mutation (Q577R/N/K) in the PIE12-trimer binding site, this
analysis identified three gp120 and four gp41 mutations
(Table 3 and Fig. 5). Of the gp120 mutations, one is a
point mutation (A48T), and two are in-frame deletions
(Δ161–164 in the V1/V2 loop and Δ396–400 in the V4
loop). The V4 loop deletion truncates a tandem duplication of 5 amino acids (FNSTWFNSTW), with only
one FNSTW copy linked with PIE12-trimer resistance.
This deletion has also been reported in a virus resistant
to T-2635, a third-generation C-peptide fusion inhibitor [15]. The four gp41 mutations are all located outside the PIE12 binding site. Two (Q550H and the silent
V583V) are located within the RRE, L663F is in the gp41

membrane-proximal external region (MPER), and A823V
is in the cytoplasmic domain between LLP-3 and LLP-1.

Discussion
This study identifies Q577R/N/K within the
gp41 N-trimer hydrophobic pocket as the primary resistance mechanism used to escape inhibition by the highly
potent d-peptide entry inhibitor PIE12-trimer. As predicted by the resistance capacitor hypothesis, the selection for high-level resistance required: (1) extended
passaging compared to those against earlier-generation
entry inhibitors, (2) a mutation that dramatically reduced
inhibitor affinity at the cost of substantially reduced
viral fitness, and (3) compensatory mutations to restore
viral fitness in the face of such a destabilizing mutation.
Despite these obstacles, HIV-1 was ultimately able to
resist PIE12-trimer in vitro.
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Fig. 5 Prominent mutations in gp120 and gp41 observed in PIE12-trimer resistant viruses. The primary structure of the Env precursor, gp160, is
depicted, with HXB2 (UniProtKB P04578) numbering. The gp41 N- and C-peptide regions are numbered according to [45]. gp160 is processed into
two non-covalently associated subunits, the surface gp120 (orange) and the membrane-spanning gp41 (blue). gp120 comprises five constant
domains (C1–C5) and five variable domains (V1-V5). gp41 contains a fusion peptide (FP), an N-peptide region that forms the N-trimer coiled coil (N),
a C-peptide region (C) that together with the N-trimer forms a 6-helix bundle in the post-fusion state, a membrane-proximal external region (MPER),
a transmembrane domain (TM), and a cytoplasmic tail (CT). The primary resistance mutations (Q577R/N/K) are represented in red, and candidate
resistance and fitness compensation mutations are shown in black. Mutations denoted by * are within the Rev Response Element (RRE)

Interestingly, even though the gp41 hydrophobic
pocket is highly conserved, in rare cases HIV-1 naturally
accommodates alternate residues at position Q577. For
example, the uncommon Group O HIV-1 strains (< 1% of
global HIV-1 infections) primarily contain Q577R. Not
surprisingly, we previously observed high-level PIE12trimer resistance in two HIV-1 Group O isolates [8].
Additionally, within the > 50,000 non-Group O sequences
from the Los Alamos HIV Sequence Database, ~ 1.4%
contain Q577R.
Q577R has also been identified in viral resistance
screens against other HIV-1 entry inhibitors that target
the prehairpin intermediate. Against N-trimer peptides
N44, N36, and IZN36, the C-peptide T2635, and the retrocyclin RC-101, Q577R is found in some [15, 21, 22] or
all [23, 24] of the resistant viruses and always accompanied by other gp41 mutation(s). By itself, Q577R provided
only modest resistance to the N-trimer and C-peptide
inhibitors (< threefold) [15, 24]. Viral escape from a
recently identified adnectin, 6200_A08, which similarly targets the gp41 hydrophobic pocket, has also been
shown to use Q577R as the primary mechanism [25].
Consistent with our results, many of these studies have
demonstrated a fitness defect for Q577R [15, 23–25].
Importantly, Q577R Env (HXB2 strain) has been shown
to be properly expressed, processed, and incorporated
into pseudovirions, so the fitness defect is likely downstream of virus production [26]. Surprisingly, genetic
analysis of the virus from a patient resistant to the FDAapproved peptide fusion inhibitor enfuvirtide also identified the Q577R mutation [27], and in the context of that
patient’s pre-treatment env, provided 25-fold resistance
to enfuvirtide. This discovery is an outlier, however, as

the primary resistance mechanism to enfuvirtide involves
mutation within gp41 residues 547–556 [11], and the
enfuvirtide sensitivity of other studied HIV-1 strains is
minimally affected by Q577R [15, 22–24]. Indeed, our
data demonstrate only modest differences in C-peptide
inhibition of Q577R compared to WT pseudoviruses,
including C34, T20 (enfuvirtide) and T1249 (Additional
file 3), and our PIE12-trimer resistant pools retain sensitivity to a related peptide, C37 (Table 1).
The Q577 mutation in the critical N-trimer region
could conceivably influence multiple stages of the entry
process, leading to its effect on viral fitness. Using multiple methods, Weiss, et al. have investigated the effect
of Q577R on Env structure and function. They have
shown that the Q577R substitution leads to: (1) a more
stable 6-helix bundle structure, (2) greater neutralization sensitivity to CD4 mimetics, and (3) decreased susceptibility to CD4-induced gp41 conformational changes
that lead to viral inactivation [21, 22, 24, 28]. This wide
influence of Q577 mutation on Env function supports the
concept that both gp120 and gp41 modifications would
be needed to restore viral fitness, as is seen in our PIE12trimer resistant pools. However, there is little overlap
between the Env modifications seen in our pools and
those in naturally occurring strains with Q577R and in
Q577R virus resistant to other entry inhibitors. As shown
in an alignment of the ~ 750 Group M primary isolate
Q577R Envs (out of > 50,000 Group M sequences from
the Los Alamos HIV Sequence Database) with our PIE12trimer resistant sequences, none of the candidate PIE12trimer-resistant compensatory mutations are prevalent in
the primary isolates (Additional file 4). Additionally, we
did not identify any overlap of our specific compensatory
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mutations with those found in the other entry-inhibitor
resistance screens with Q577R virus [15, 22–24].
Although none of our specific compensatory mutations
are found in Q577R viruses resistant to other entry inhibitors, it seems likely that similar compensation mechanisms are used. In previous entry inhibitor resistance
studies that include Q577R and for which gp120 sequence
is available [15, 21–23, 28], compensatory mutations are
found in CD4 binding residues (E426K), the V1/V2 loop
(D167N), and in the V3 loop (R298K, S306G, I309M,
T319I, and E322D), indicating that changes to gp120based fusion determinants, such as CD4 and co-receptor
binding, help restore gp41-based fitness defects. Our V1/
V2 and V4 loop deletions may similarly affect Env function. Additionally, several V3 loop mutants that are similar to those identified in other resistance selections were
found in some of our sequences (S306R, T319A).
The region of the HIV genome that encodes the highly
conserved hydrophobic pocket (the target of PIE12)
also encodes part of the Rev-Response Element (RRE),
whose specific RNA structure is required for proper
viral replication. By analyzing nucleotide accessibility to
chemical modification, Legiewicz et al. [29] previously
showed silent mutation at Q577 (codon CAG to CAA) is
sufficient to induce structural changes in the RRE, specifically in stem loops III–V. Although our nucleotide
sequences differ from that in the Legiewicz study (codon
CGG for Q577R and AAC for Q577N), we similarly postulate an RRE structural rearrangement centered at the
base of stem-loop V [30], the location of the 577 codon,
that likely contributes to the fitness defect. Interestingly,
Q550H and Q577R/N/K are observed in nearly all PIE12trimer resistant sequences. The presence of additional
mutations within the RRE, namely Q550H and a silent
mutation at V583(GTG→GTA), suggest these may play
an important compensatory role in restructuring the
RRE. Indeed, the structural rearrangement induced by
Q577 mutation seen by Legiewicz was maintained with
a silent mutation at Q550. However, Q550 mutations are
not observed in any of the 689 Q577R-containing primary isolates (Additional file 4). Residue 583 is variable
in the Q577R-containing primary isolates, although only
hydrophobic residues (valine, isoleucine, leucine, and
methionine) are observed.
Compensatory mutations to changes in the RRE could
also be found in Rev, which binds the RRE to promote
the export of mRNA from the nucleus. Although our
sequence analysis focused on mutations in env, 80%
of the Rev sequence (exon 2) is encoded within this
same genomic region. Three Rev mutations (env positions 2354, 2375 and 2435, leading to N86Y, G93W, and
G113R in Rev while silent in Env) surfaced in our initial analysis (Additional file 1), but each is present in
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only one resistant pool, none are fully penetrant, and all
are located in the predicted disordered nuclear export
sequence [31]. Sequencing of rev exon 1 and functional
studies of mutant Rev/RRE will be required to see if there
are any meaningful compensatory changes in Rev.
We have also sought to improve the overall potency
and breadth of PIE12-trimer by conjugating it to cholesterol (chol-PIE12-trimer) to concentrate it at cell membrane lipid rafts, the site of viral entry. This modification
increases its association rate for the prehairpin intermediate and improves potency ~ 100-fold [10]. Additionally, cholesterol conjugation prolongs the in vivo half-life
of the inhibitor, making it suitable for extended-release
delivery [32]. With its improved potency, chol-PIE12trimer is better able to combat PIE12-trimer resistant
virus and inhibits pseudovirions with the Q577R mutation with a low nanomolar 
IC50 [10]. However, our
preliminary viral passaging studies in the presence of
chol-PIE12-trimer suggest that high-level resistant virus
ultimately emerges. Like for the PIE12-trimer resistant
viruses, the pathway to resistance against chol-PIE12trimer includes mutation of Q577, and no other pocket
mutations were observed. We are currently studying the
additional mutations acquired during chol-PIE12-trimer
passaging to understand the mechanism of resistance
against this potential clinical candidate.
Ultimately, we hope to use the data described here to
develop next-generation d-peptide inhibitors that anticipate this route of resistance to create an even higher barrier to resistance. Efforts are underway to discover novel
d-peptide entry inhibitors that maintain high affinity to
both the native and Q577R pockets.

Conclusion
Although our highly potent, broad d-peptide entry inhibitor, PIE12-trimer, exhibits a high barrier to resistance,
with extended passaging (> 1 year) we eventually obtained
HIV-1 resistant to PIE12-trimer. The primary resistance
mutation, Q577R/N/K, is found in the conserved PIE12trimer binding pocket on the gp41 N-trimer. Q577R disrupts two hydrogen bonds between PIE12-trimer and
the inhibitor-binding pocket and substantially decreases
binding affinity. Q577 mutation confers a significant fitness defect as seen by delayed viral replication. The
highly resistant polyclonal viral pools exhibit rescued
fitness due to compensatory mutations found in gp120
and gp41. Using deep sequencing analysis, we identified
seven potential compensatory mutations, which will be
the focus of future mechanistic studies. Possible compensatory mechanisms include modifications to viral entry
steps, such as receptor and co-receptor binding, fusion
kinetics, Env folding, and interactions between Rev and
the RRE.
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Methods
Passaging studies

PIE12-trimer resistant viruses were acquired in a previous study [8]. Briefly, CEM-1 cells were infected with
the laboratory-adapted HIV-1 strain NL4-3 (obtained
from Dr. Malcolm Martin, Cat #114, NIH AIDS Reagent Program). Virus was serially propagated weekly
by adding a 1:5 dilution of cell-free viral supernatant to
fresh CEM-1 cells in the presence or absence (control)
of PIE12-trimer. Viral titers were monitored biweekly by
p24 antigen ELISA (PerkinElmer). The initial inhibitor
concentration was 1 nM (near the PIE12-trimer IC50).
When p24 antigen levels in PIE12-trimer-containing cultures approached the level seen in inhibitor-free (control)
cultures (typically 5–15 weeks), PIE12-trimer concentrations were raised approximately 1.5- to 2-fold. Ultimately, two polyclonal viral pools able to propagate in
the presence of 320 nM PIE12-trimer (W1 and W2) were
obtained. These pools were propagated in CEM-GFP
cells for 48 h then isolated and concentrated over a 20%
sucrose cushion.
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using the HIV-1 p24 Antigen Capture Assay (Advanced
Bioscience Laboratories) and confirmed by X-gal staining
of infected TZM-bl cells.
Generation of envelope cDNA for Sanger and deep
sequencing

Viral RNA was isolated from the W1, W2, and control
viral pools with the E.Z.N.A.® Viral RNA Kit (Omega BioTek). Env cDNA was generated using the SuperScript®
III One-Step RT-PCR System with Platinum® Taq High
Fidelity (Invitrogen). Barcoded primers were designed
using Primer3Plus (RT Primer: GCC
TTG
CCA
GCA
CGCTCAGGCCTTGCATAGTAGCNNNNNNNNATG
AGAGTGAAGGAGAAGTATCAGC and PCR primer
FWD: GCCTTGCCAGCACGCTCAGGC) [33]. For
Sanger sequencing, the env cDNA was cloned into standard vectors via two strategies. First pEBB backbone was
used with NotI/XhoI sites. For increased efficiency, we
also used TOPO cloning. Individual plasmid clones were
sequenced by the DNA Sequencing Core Facility (University of Utah).
For deep sequencing, the cDNA was purified by agarose gel electrophoresis, extracted (GenElute™ Gel
Cells and viruses
TZM-bl cells that express luciferase and β-galactosidase Extraction Kit, Sigma), and submitted to the Highin response to HIV-1 promoter activation (obtained Throughput Genomics and Bioinformatic Analysis Core
from Dr. John C. Kappes and Dr. Xiaoyun Wu, Cat Facility (Huntsman Cancer Institute, University of Utah)
#8129, NIH AIDS Reagent Program) and 293T cells were for library preparation and sequencing. Barcoded samgrown in Dulbecco’s modified Eagle media. CEM-GFP ples were multiplexed in a single lane and sequenced on
cells that express GFP in response to HIV-1 LTR acti- an Illumina HiSeq 2000 (50 cycle single-end reads). The
vation (obtained from Dr. Jacques Corbeil, Cat #3655, raw sequencing reads in FASTQ format were mapped to
NIH AIDS Reagent Program) were grown in RPMI 1640 nucleotides 6195–8826 from the HIV-1 vector pNL4-3
media. The Q577R, Q577N and Q577K point mutant sequence (GenBank: AF324493.2) using STAMPY [34]. A
viral vectors were generated by excising the env region summary of base calls for each position of the reference
of the WT pNL4-3 genome using XhoI and EcoRI (NEB) sequence was generated by converting the alignment
and ligating into pET20b (Novagen), a shuttle vector data to pileup format using the SAMtools:mpileup funcwe used for mutagenesis. The point mutants (CGG for tion (used -BQ0 and -d 2,000,000 options). Custom Perl
Q577R, AAG for Q577K and AAC for Q577N) were scripts were used to convert base calls at each position
introduced using the Q5 site-directed mutagenesis kit from pileup format to a more intuitive table and then to
with primers designed using NEBuilder software (NEB). filter the data to display only those positions where deviaThe Q577R forward and reverse primers were CAA tions from the reference are present in the population
ACAGCTCCGGGCAAGAATCC and ATGCCCCAG above a user-defined threshold (10%).
ACTGTGAGTT. The Q577N forward and reverse primers were CAAACAGCTCAACGCAAGAATCCTGG Peptide synthesis
and ATGCCCCAGACTGTGAGT. The Q577K forward All synthetic peptides were acetylated at the N-terminus
primer was CAAACAGCTCAAGGCAAGAATCC, and amidated at the C-terminus. All reverse-phase HPLC
and the reverse primer was the same as that for Q577N. (RP-HPLC) purifications were performed on a Waters
Mutated clones were confirmed by Sanger sequencing, C18 column (BEH X-Bridge, 19 × 250 mm, 10 µm, 300
and the desired mutants were ligated back into the WT Å) with water/acetonitrile gradient in 0.1% TFA unless
pNL4-3 backbone after EcoRI/XhoI digestion. Env in the otherwise noted. KG-PIE12 was synthesized by the Unifinal Q577-mutated pNL4-3 constructs was confirmed by versity of Utah DNA/Peptide Core as described in [8]
Sanger sequencing. These vectors were then transfected and purified via RP-HPLC on a Vydac C18 column (TP,
into 293T cells using Fugene HD (Promega) to generate 22 × 250 mm, 10 µm, 300 Å). PIE12-GK and PIE12replication-competent virus. Viral titers were measured trimer were synthesized as previously described [8].
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SelMet-IQN17-Q577R and HIV C34 were synthesized
on a PS3 peptide synthesizer (Protein Technologies,
Inc.) at 80 µmol scale on NovaPEG Rink Amide LL resin
(Novabiochem) and Rink Amide AM resin LL (Novabiochem), respectively, via Fmoc-SPPS and were purified by
RP-HPLC.
Recombinant protein production

Cys-Gly-Gly-Asp-IZN36 (derived from HXB2 strain)
with a thrombin-cleavable His tag was prepared as previously described [8]. A Q577R mutant version was
generated via site-directed mutagenesis using the
QuikChange® protocol (Stratagene). Protein expression
was performed in BL21 (DE3) cells (Novagen) following
Studier’s autoinduction protocol [35]. Inclusion bodies
containing IZN36 were solubilized in 20 mM sodium
phosphate pH 8.0, 300 mM NaCl, 10 mM imidazole, 6 M
GuHCl, and sonicated. IZN36 was then purified using
His-Select Ni-affinity resin (Sigma). Ni-purified samples
were dialyzed into water with 0.1% TFA and purified
via RP-HPLC on a Waters C18 column (BEH X-Bridge,
19 × 250 mm, 10 µm, 300 Å) with water/acetonitrile gradient in 0.1% TFA and lyophilized. The cysteine residues
of these constructs were biotinylated for SPR. Reactions
were carried out in PBS pH 7.0 with ~ 1–2 mg/mL protein
and a 15X molar excess of Biotin-dPEG®3-MAL (Quanta
BioDesign) at room temp for 1 h, followed by RP-HPLC
purification. The His tag was cleaved in PBS pH 6.3 with
10 µM heparin at a protein concentration of ~ 0.8 mg/
mL and one unit of thrombin protease (GE Healthcare)
per mg of protein. The cleavage reaction was incubated
at 37 °C with agitation for 44 h followed by RP-HPLC as
above.
Surface plasmon resonance analysis

Protein interaction analysis was carried out on a Biacore
3000 (GE Healthcare). Analyses were performed in triplicate at 25 °C in sterile-filtered and degassed Gibco®
PBS pH 7.4 (Invitrogen) supplemented with 0.005% P20
and 1 mg/mL BSA at a flow rate of 50 μL/min. First,
streptavidin (Pierce) was immobilized on CM5 chips
(GE Healthcare) using the Amine Coupling Kit (GE
Healthcare) following a standard coupling protocol [36].
Stocks (~ 50 nM) of biotinylated IZN36 (WT and Q577R
mutant) were prepared in running buffer in the presence of 1.2x molar excess of HIV C34 and captured on
the surface to a density of 100–200 RUs. Loading IZN36
in the presence of C34 results in better behaved surfaces,
and C34 was removed by surface regeneration with 0.1%
SDS injections. The active surface and a streptavidinderivatized control surface were blocked with d-biotin.
Stock solutions of PIE12-GK were prepared at 50 μM in
running buffer, from which samples in the concentration
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series were generated by serial dilution (three-fold to
2.54 nM). Injections were performed for 1 min using
KINJECT. Dissociation was monitored for 2 min, followed by a 20 μL injection (QUICKINJECT) of running
buffer followed by EXTRACLEAN. Sensorgrams were
processed using Scrubber2 (BioLogic Software), and
data were analyzed with Prism 5.0 (GraphPad Software).
The equilibrium binding data were fit using the built-in
saturation binding model (one site—specific binding),
normalized to Bmax, and replotted as concentration of
analyte vs. % capacity.
Crystallography

KG-PIE12 was crystallized in complex with Se-MetIQN17-Q577R (1:1.1 IQN17:KG-PIE12, 10 mg/mL total
in water) at 21 °C in Hampton Research condition SaltRx
HT B4 (1.8 M ammonium citrate dibasic, 0.1 M sodium
acetate trihydrate, pH 4.6) by sitting-drop vapor diffusion. Several crystals were mounted in nylon loops and
cryocooled following a 20 s immersion in 20 μL crystallization buffer with 0–10% added glycerol. Data were
collected from a single crystal judged by integration
of test images to produce the best diffraction. Crystals
were maintained at 100 K during data collection. Data
collection was performed at the Stanford Synchrotron
Radiation Lightsource (SSRL) beam line 7-1. Data were
processed using HKL2000 [37]. The IQN17-Q577R/
PIE12 structure was determined by molecular replacement using PHASER [38] with PIE12-IQN17 (PDB structure 3L37) as the search model. The model was rebuilt
using O [39] and COOT [40] and refined against a maximum-likelihood target function using PHENIX [41]. The
structure was checked using the MolProbity program
[42]. See Table 2 for crystallographic data and refinement statistics. Buried surface area was calculated with
the program Naccess V2.1.1 [43]. For compatibility with
Naccess, the surface areas were calculated with the ACE
and NH2 modified ends removed, and the names of the
d-amino acid residues changed to their cognate l-amino
acids, without changing the coordinates.
Growth assay

CEM-GFP cells were infected with 1 ng p24 of either
clonal pNL4-3, one of the Q577 point mutant viruses,
or one of the polyclonal viral pools (W1 or W2) with
DEAE dextran (8 µg/mL) and incubated at 37 °C for 2 h.
Cells were then pelleted (2000 x g, for 5 min), supernatant was removed, and cells were resuspended in
fresh media. Cells were incubated for 3 days, then the
medium was changed every day for the next 7 days. Viral
supernatant was collected on days 3, 5, 7, and 9 postinfection, and RNA was extracted using E.Z.N.A.® Viral
RNA Kit (Omega Bio-Tek). Viral levels were measured
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by qRT-PCR (Lightcycler 480, Roche) with primers targeting a conserved region of Gag and compared to a
standard curve of samples with known quantities of p24.
Viral inhibition assays

Viral infectivity was measured as previously described
[44], with the following changes. Replication-competent
viruses were added to TZM-bl cells in the presence of a
tenfold dilution series of PIE12-trimer (100 nM to 10 pM
for WT virus, 100 µM to 10 nM for resistant virus, from
PIE12-trimer stock in 50 mM HEPES pH 7.4) and 8 µg/
mL DEAE dextran. Medium was removed after 30 h, and
cells were lysed with Glo Lysis buffer (Promega). BrightGlo luciferase substrate (Promega) was added and luminescence was measured (POLARstar Optima, BMG).
TZM-bl cells exhibit significant background luminescence, so uninfected wells were used for background
subtraction. Luciferase activity was normalized to uninhibited controls, and IC50 values were determined from
a fit to a Langmuir equation: y = 1/(1 + [inhibitor]/IC50)
weighted by the normalized standard error of replicates
within an assay (with a minimum 1% error) using Prism
7.04 (GraphPad).
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Additional file 1. Mutations observed in PIE12-trimer resistant viral pools.
Env gene position (pNL4-3 numbering), reference base, and all base calls
for control and PIE12-trimer resistance viral populations with a mutation > 10% of the population (with percentage of the base calls for each
position colored on a spectrum from low (light pink) to high (red)) are
indicated. Additionally, the positions are annotated by their location in Env
according to the following categories: known or putative glycosylation
site (green), gp120 variable loops (gray), chemokine receptor (co-receptor)
binding site (blue), rev-response element (dark gray), gp41 N-trimer
(orange), gp41 C-peptide region (light blue), or the Rev coding region
included within the env gene (yellow). Eighty-one positions were identified. Of these, 74 conform to our analysis criteria (found in the resistant
pool(s) and > 10% different frequency than in the control pool).
Additional file 2. SPR sensorgrams for PIE12 monomer binding to IZN36
WT (left panel) or Q577R (right panel), processed in Scrubber2 (BioLogic
Software) and used for the equilibrium fit shown in Fig. 2. Six threefold
dilutions of PIE12 monomer (617 nM to 2.54 nM) were flowed over the WT
surface, and ten threefold dilutions (50 µM to 2.54 nM) were flowed over
the Q577R surface. The calculated K D’s are 0.031 µM for WT and 2.0 µM for
Q577R.
Additional file 3. Effect of Q577R on C-peptide Inhibitors. Single-cycle
viral infectivity assays in which HIV-1 HXB2 Env (WT and Q577R) pseudotyped HIV-1 with a luciferase reporter was used to infect HOS-LES cells in
the absence or presence of six fivefold dilutions of the indicated C-peptide
(in quadruplicate). The data are the average of two experiments with the
standard deviation in parentheses.
Additional file 4. Prevalence of PIE12-trimer resistant candidate compensatory amino acid mutations in Group M primary isolates containing
Q577R.
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